Hajime Kojima

Dr. Hajime Kojima


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
MDM.P. Dent
M.P. Dent
EVE. Vaillancourt
E. Vaillancourt
RTR.S. Thomas
R.S. Thomas
PCP.L. Carmichael
P.L. Carmichael
GOG. Ouedraogo
G. Ouedraogo
CYC. Yang
C. Yang
Next generation risk assessment (NGRA) is an exposure-led, hypothesis-driven approach that has the potential to support animal-free safety decision-making. However, significant effort is needed to develop and test the in vitro and in silico (computational) approaches that underpin NGRA to enable confident application in a regulatory context. A workshop was held in Montreal in 2019 to discuss where effort needs to be focussed and to agree on the steps needed to ensure safety decisions made on cosmetic ingredients are robust and protective. Workshop participants explored whether NGRA for cosmetic ingredients can be protective of human health, and reviewed examples of NGRA for cosmetic ingredients. From the limited examples available, it is clear that NGRA is still in its infancy, and further case studies are needed to determine whether safety decisions are sufficiently protective and not overly conservative. Seven areas were identified to help progress application of NGRA, including further investments in case studies that elaborate on scenarios frequently encountered by industry and regulators, including those where a 'high risk' conclusion would be expected. These will provide confidence that the tools and approaches can reliably discern differing levels of risk. Furthermore, frameworks to guide performance and reporting should be developed.

1 June 2018 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
ADAmber B. Daniel
Amber B. Daniel
Judy StricklandJudy Strickland
Judy Strickland
DADavid Allen
David Allen
SCSilvia Casati
Silvia Casati
VZValérie Zuang
Valérie Zuang
NKNicole Kleinstreuer
Nicole Kleinstreuer

23 September 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
KMKenta Mizoi
Kenta Mizoi
HAHiroshi Arakawa
Hiroshi Arakawa
KYKentaro Yano
Kentaro Yano
SKSatoshi Koyama
Satoshi Koyama
Hajime KojimaHajime Kojima
Hajime Kojima
TOTakuo Ogihara
Takuo Ogihara
This paper reviews the usefulness, current status, and potential of primary human hepatocytes (PHHs) in three-dimensional (3D) cultures, also known as spheroids, in the field of pharmacokinetics (PK). Predicting PK and toxicity means pharmaceutical research can be conducted more efficiently. Various in vitro test systems using human hepatocytes have been proposed as tools to detect hepatic toxicity at an early stage in the drug development process. However, such evaluation requires long-term, low-level exposure to the test compound, and conventional screening systems such as PHHs in planar (2D) culture, in which the cells can only survive for a few days, are unsuitable for this purpose. In contrast, spheroids consisting of PHH are reported to retain the functional characteristics of human liver for at least 35 days. Here, we introduce a fundamental PK and toxicity assessment model of PHH spheroids and describe their applications for assessing species-specific metabolism, enzyme induction, and toxicity, focusing on our own work in these areas. The studies outlined in this paper may provide important information for pharmaceutical companies to reduce termination of development of drug candidates.

10 October 2013 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
Hajime KojimaHajime Kojima
Hajime Kojima
MKMasakazu Katoh
Masakazu Katoh
SSShinsuke Shinoda
Shinsuke Shinoda
SHSaori Hagiwara
Saori Hagiwara
TSTamie Suzuki
Tamie Suzuki
ASAya Shibai
Aya Shibai

1 March 2012 in Alternatives to Laboratory Animals
Verified
Journal Article
Closed access
PDF file
Hajime KojimaHajime Kojima
Hajime Kojima
YAYoko Ando
Yoko Ando
KIKenji Idehara
Kenji Idehara
MKMasakazu Katoh
Masakazu Katoh
TKTadashi Kosaka
Tadashi Kosaka
TOTakashi Omori
Takashi Omori
A validation study on an in vitro skin irritation assay was performed with the reconstructed human epidermis (RhE) LabCyte EPI-MODEL24, developed by Japan Tissue Engineering Co. Ltd (Gamagori, Japan). The protocol that was followed in the current study was an optimised version of the EpiSkin protocol (LabCyte assay). According to the United Nations Globally Harmonised System (UN GHS) of classification for assessing the skin irritation potential of a chemical, 12 irritants and 13 non-irritants were validated by a minimum of six laboratories from the Japanese Society for Alternatives to Animal Experiments (JSAAE) skin irritation assay validation study management team (VMT). The 25 chemicals were listed in the European Centre for the Validation of Alternative Methods (ECVAM) performance standards. The reconstructed tissues were exposed to the chemicals for 15 minutes and incubated for 42 hours in fresh culture medium. Subsequently, the level of interleukin-1 alpha (IL-1α) present in the conditioned medium was measured, and tissue viability was assessed by using the MTT assay. The results of the MTT assay obtained with the LabCyte EPI-MODEL24 (LabCyte MTT assay) demonstrated high within-laboratory and between-laboratory reproducibility, as well as high accuracy for use as a stand-alone assay to distinguish skin irritants from non-irritants. In addition, the IL-1α release measurements in the LabCyte assay were clearly unnecessary for the success of this model in the classification of chemicals for skin irritation potential.

1 September 2013 in Toxicology in Vitro
Verified
Journal Article
Closed access
Hajime KojimaHajime Kojima
Hajime Kojima
KHKazuhiko Hayashi
Kazuhiko Hayashi
HSHitoshi Sakaguchi
Hitoshi Sakaguchi
TOTakashi Omori
Takashi Omori
TOTakuya Otoizumi
Takuya Otoizumi
TMTakashi Morimoto
Takashi Morimoto